| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Clement Chung | Q60189734 |
| P2093 | author name string | Clement Chung | |
| P2860 | cites work | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 |
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Q27851751 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Q27852787 | ||
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer | Q27853013 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| EGF receptor | Q28646107 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. | Q34004737 | ||
| Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. | Q34116750 | ||
| Epidermal growth factor receptor signaling | Q34258444 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. | Q34545921 | ||
| Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. | Q34545926 | ||
| Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. | Q34785001 | ||
| Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer | Q35043706 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors | Q36191575 | ||
| The epidermal growth factor receptor family | Q36236606 | ||
| First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial | Q36368641 | ||
| Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q36412597 | ||
| Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer | Q36422709 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies | Q36660664 | ||
| Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer | Q36732046 | ||
| Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer | Q36948707 | ||
| Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. | Q37130325 | ||
| LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both | Q38118503 | ||
| Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Q38245038 | ||
| Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In | Q38259724 | ||
| Somatic mutations of the ERBB4 kinase domain in human cancers | Q38512879 | ||
| Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 | ||
| Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
| Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer | Q40558929 | ||
| Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. | Q43056663 | ||
| Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer | Q44459241 | ||
| Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study | Q46380513 | ||
| Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib | Q46934958 | ||
| Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy | Q46966658 | ||
| A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. | Q50976951 | ||
| Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. | Q54339119 | ||
| Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. | Q54618926 | ||
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. | Q54620289 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 461-476 | |
| P577 | publication date | 2015-04-08 | |
| P1433 | published in | Journal of Oncology Pharmacy Practice | Q6295681 |
| P1476 | title | Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics | |
| P478 | volume | 22 |
| Q48248991 | 18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. |
| Q54977989 | Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells. |
| Q52653002 | Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. |
| Q50192132 | Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma |
| Q28387027 | Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer |
| Q26769884 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential |
| Q47566249 | Precision medicine: does ethnicity information complement genotype-based prescribing decisions? |
| Q47994454 | Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer |
| Q33671632 | Reduction of miR‑132‑3p contributes to gastric cancer proliferation by targeting MUC13. |
| Q64902059 | Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. |
| Q37432540 | Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. |
| Q41472736 | The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. |
Search more.